Advertisement
News
Advertisement

Covidien Completes Sale of Specialty Chemicals Business

Mon, 08/30/2010 - 3:33am
Covidien

DUBLIN, Aug 30, 2010 (BUSINESS WIRE) --

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced sale of its Specialty Chemicals business to an affiliate of New Mountain Capital, L.L.C. for a cash purchase price of approximately $280 million.

The decision to divest Specialty Chemicals was made following a thorough evaluation of a number of strategic alternatives. The decision is consistent with Covidien's strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the Company has or can develop a global competitive advantage.

The business is currently reported as a discontinued operation and the transaction is not expected to have a material effect on Covidien's operating income or earnings per share for fiscal 2010 or 2011.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2009 revenue of $10.3 billion, Covidien has 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading